Inovio Pharmaceuticals, Inc.
INO
$2.05
$0.105.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.52% | -73.82% | -76.17% | -93.85% | -92.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.52% | -73.82% | -76.17% | -93.85% | -92.95% |
| Cost of Revenue | -6.14% | -10.71% | -26.99% | -39.63% | -53.40% |
| Gross Profit | 5.61% | 10.08% | 26.60% | 35.19% | 50.74% |
| SG&A Expenses | -10.40% | -11.46% | -3.47% | -4.84% | -45.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.60% | -10.96% | -21.15% | -31.61% | -51.04% |
| Operating Income | 7.27% | 10.54% | 20.82% | 27.76% | 49.14% |
| Income Before Tax | 22.78% | 20.62% | 31.41% | 27.78% | 48.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.78% | 20.62% | 31.41% | 27.78% | 48.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.78% | 20.62% | 31.41% | 27.78% | 48.24% |
| EBIT | 7.27% | 10.54% | 20.82% | 27.76% | 49.14% |
| EBITDA | 6.80% | 9.95% | 20.38% | 27.46% | 49.33% |
| EPS Basic | 41.56% | 34.04% | 41.14% | 35.55% | 53.27% |
| Normalized Basic EPS | 31.81% | 24.42% | 31.57% | 36.26% | 55.95% |
| EPS Diluted | 41.47% | 33.99% | 41.10% | 35.51% | 53.28% |
| Normalized Diluted EPS | 31.81% | 24.42% | 31.57% | 36.26% | 55.95% |
| Average Basic Shares Outstanding | 37.05% | 22.48% | 16.73% | 12.18% | 9.22% |
| Average Diluted Shares Outstanding | 37.05% | 22.48% | 16.73% | 12.18% | 9.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |